Publication
Article
Improving the Quality of Life in Patients With Multiple Sclerosis: New Strategies and Opportunities
This supplement to The American Journal of Managed Care discusses unmet needs in improving quality of life in patients with MS. Also discussed is the management of specific MS symptoms, including fatigue, spasticity, and impaired mobility. Patients have reported that mobility impairment is one of the worst aspects of MS. Dalfampridine received FDA approval for all forms of MS specifically to improve walking; improved walking could potentially help contain some of the direct and indirect costs associated with MS care.
Faculty
Joseph R. Berger, MD
Ruth L. Works Professor and Chairman
Department of Neurology
University of Kentucky College of Medicine
Lexington, Kentucky
Augusto A. Miravalle, MD
Assistant Professor
Department of Neurology
University of Colorado School of Medicine
Aurora, Colorado
Jennifer Smrtka, MSN, ANP-BC, MSCN
Adult Nurse Practitioner
Fort Lauderdale Multiple Sclerosis Center
Pompano Beach, Florida
Howard L. Zwibel, MD
Founding Medical Director, Emeritus
Neuroscience Consultants
Comprehensive Multiple Sclerosis Center in affiliation with the National Multiple Sclerosis Center
Baptist Health Doctors Hospital Multiple Sclerosis Center
Coral Gables, Florida
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Joseph R. Berger, MD
Advisory board/consultant: Bayer, Biogen Idec, Eisai, Genentech, Millenium, Novartis, Perseid Therapeutics, Pfizer
Grants/honoraria: Bayer, Biogen Idec, EMD Serono
Augusto A. Miravalle, MD
Consultant: Advanced Studies in Medicine, Bayer, Biogen Idec, EMD Serono, Novartis, Questcor
Jennifer Smrtka, MSN, ANP-BC, MSCN
Board membership: International Organization of Multiple Sclerosis Nurses
Honoraria: Acorda Therapeutics, Inc, Bayer HealthCare, EMD Serono, Pfizer, Teva, Questcor, Novartis, PRIME, Consensus Medical, National Multiple Sclerosis Society, Multiple Sclerosis Association of America
Lectureship: Acorda Therapeutics, Inc
Howard L. Zwibel, MD
Advisory board/consultant: Acorda Therapeutics, Inc, Medscape, Teva Neuroscience
Honoraria: Acorda Therapeutics, Inc, Medscape, PRIME, Teva
Lectureship: Teva
This supplement was supported by Acorda Therapeutics, Inc.
Authors and subject matter contained in this supplement were determined by The American Journal of Managed Care publishing staff.
Publisher’s Note
The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of The American Journal of Managed Care. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.